Terug naar bedrijfspagina

Nieuws over Tubize (Financière De)

22/03/2025 Tubize - jaarverslag 2024 (22.03.2025)

19/03/2025 UCB - Nieuwe gegevens over experimentele therapie voor thymidinekinase 2-deficiëntie gepresenteerd op de Muscular Dystrophy Association (MDA) 2025-conferentie (19.03.2025)

27/02/2025 UCB - Media Room: 2024 Full Year Results (UCB Media Room: Resultaten voor het volledige jaar 2024) (27.02.2025)

12/02/2025 UCB - Media Room: BIMZELX bimekizumab) two-year data in HS at EHSF 2025 (UCB Media Room: BIMZELX (bimekizumab) tweejarige gegevens in HS op EHSF 2025) (12.02.2025 )

10/02/2025 UCB - Media Room: UCB Advances Long-Term Innovation Strategy with New Research & Development Facility at Braine-l’Alleud Campus (10.02.2025)

31/01/2025 UCB -RYSTIGGO(rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods (31.01.2025)

15/01/2025 UCB - showcases decade of growth and Patient Value Strategy driving differentiated innovation (15.01.2025)

09/01/2025 UCB - Media Room: partnership with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform (09.01.2025)

16/12/2024 UCB - Media Room: Findings from minzasolmin proof-of-concept ORCHESTRA study shape next steps in UCB Parkinson’s research program (16.12.2024)

27/11/2024 UCB - Media Room: latest scientific research in epilepsy presented at American Epilepsy Society (AES) Annual Meeting (27.11.2024)

20/11/2024 UCB - receives U.S. FDA approval for BIMZELX® (bimekizumab-bkzx) as the first IL-17A and IL-17F inhibitor for adults with moderate to severe hidradenitis suppurativa (20.11.2024)

19/11/2024 UCB - Media Room: Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology (19.11.2024)

05/11/2024 UCB - Media Room: UCB completes sale of established brands and updates 2024 financial guidance (05.11.2024)

22/10/2024 UCB - Announces Bepranemab Phase 2a Study Results Accepted for Late-Breaking Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting (22.10.2024)

14/10/2024 UCB - receives U.S. FDA approval for 320 mg single-injection device presentations of BIMZELX (bimekizumab-bkzx) (14.10.2024)

11/10/2024 UCB - showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting (11.10.2024)

04/10/2024 UCB - Media Room: Transparency notification BlackRock, Inc. (04.10.2024)

02/10/2024 UCB - Transparantieverklaring BlackRock, Inc. (02.10.2024)

01/10/2024 UCB - Transparantieverklaring BlackRock, Inc. (0110.24)

30/09/2024 UCB - announces a head-to-head study evaluating BIMZEL(bimekizumab) versus SKYRIZI (risankizumab) in active psoriatic arthritis (30.09.2024)

27/09/2024 UCB - Media Room: late-breaking two-year data for BIMZEL(bimekizumab) in moderate to severe hidradenitis suppurativa at EADV 2024 (27.09.2024)

27/09/2024 UCB - Transparantieverklaring BlackRock, Inc. (27.09.2024)

26/09/2024 UCB - Media Room: Transparency notification BlackRock, Inc. (26.09.2024)

25/09/2024 UCB - Media Room: Transparency notification BlackRock, Inc. (25.09.2024)

25/09/2024 UCB - Media Room: New 4-year data for BIMZELX (bimekizumab) in moderate to severe plaque psoriasis at EADV 2024 (25.09.2024)

24/09/2024 UCB - Media Room: Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in SLE (24.09.2024)

23/09/2024 UCB - announces U.S. FDA approvals for BIMZELX (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis (23.09.2024)

09/09/2024 UCB - New insights highlight unmet needs for people living with Lennox-Gastaut syndrome and significant burden of the disease (09.09.2024)

07/09/2024 UCB - Transparantieverklaring BlackRock, Inc.(07.09.2024)

06/09/2024 UCB - Media Room: Transparency notification BlackRock, Inc.(06.09.2024)

06/09/2024 UCB - Media Room: new data across expansive epilepsies portfolio at 15th European Epilepsy Congress (EEC) (06.09.2024)

05/09/2024 UCB - Transparantieverklaring BlackRock, Inc.(05.09.2024)

03/09/2024 UCB - Transparantieverklaring BlackRock, Inc. (03.09.2024)

29/08/2024 UCB - Media Room: Transparency notification BlackRock, Inc. (29.08.2024)

26/08/2024 UCB - Media Room: UCB to Accelerate Innovation and Strategic Partnerships, Divesting Mature Product Portfolio in China

24/08/2024 UCB - Transparantieverklaring BlackRock, Inc. (24.08.2024)

22/08/2024 UCB- Transparantieverklaring BlackRock, Inc. (22.08.2024)

10/08/2024 UCB - Media Room: Transparency notification (10.08.2024)

09/08/2024 UCB - Transparantieverklaring Goldman Sachs (09.08.2024)

08/08/2024 UCB - Transparency notification Goldman Sachs (08.08.2024)

05/08/2024 UCB announces European Commission approval for 320 mg device presentations of BIMZELX(bimekizumab) - 05.08.2024

25/07/2024 UCB - Sterke start van UCB’s decennium van groei (25.07.2024)

28/06/2024 UCB - spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN) (28.06.2024)

26/06/2024 UCB - epilepsy drug BRIVIACT(brivaracetam)1 approved in Japan for treatment of focal onset seizures (26.06.2024)

13/06/2024 UCB -New data support the value of CIMZIA for women living with chronic rheumatic diseases throughout pregnancy and postpartum, and for people living with RA and high rheumatoid factor levels (13.06.2024)

12/06/2024 UCB - to share first presentations of BIMZELX(bimekizumab) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 (12.06.2024)

10/06/2024 UCB - Global experts release new guidelines on prevention of progression of epileptic seizures, addressing critical treatment gaps (10.06.2024)

31/05/2024 UCB - announces positive CHMP opinion for two 320 mg device presentations of BIMZELX (bimekizumab) (31.05.2024)

23/05/2024 UCB - announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa (23.05.2024)

18/05/2024 UCB - Media Room: Transparency notification Wellington (18.05.2024)

08/05/2024 UCB - Media Room: UCB presents final open-label extension F®▼(fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting (08.05.2024)

25/04/2024 UCB - off to a Good Start into 2024 – Progressing on its Growth Path for a Decade Plus (25.04.2024)

25/04/2024 UCB - off to a Good Start into 2024 – Progressing on its Growth Path for a Decade Plus (25.04.2024)

25/04/2024 UCB - Media Room UCB’s General Meeting of Shareholders 2024 (25.04.2024

24/04/2024 UCB - Transparantieverklaring FMR LLC (24.04.2024)

22/04/2024 UCB - receives European Commission approval for BIMZELX▼(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa (22.04.2024)

17/04/2024 UCB - FINTEPLA (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) (17.04.2014)

12/04/2024 UCB - Media Room: UCB presents new data highlighting developments across expansive neurology portfolio at 76th AAN Annual Meeting (12.04.2024)

12/04/2024 UCB - Media Room: Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY(romosozumab) can help to close the treatment gap in osteoporosi (12.04.2024)

23/05/2018 Financière de Tubize: upgrade van 'houden' naar 'kopen' (BNP Paribas Fortis)